Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Use of Dual X-ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk.

Sinclair M, Hoermann R, Peterson A, Testro A, Angus PW, Hey P, Chapman B, Gow PJ.

Liver Int. 2019 Feb 12. doi: 10.1111/liv.14071. [Epub ahead of print]

PMID:
30746903
2.

The Effects of Diabetes and High-Fat Diet on Polymodal Nociceptor and Cold Thermoreceptor Nerve Terminal Endings in the Corneal Epithelium.

Alamri AS, Brock JA, Herath CB, Rajapaksha IG, Angus PW, Ivanusic JJ.

Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):209-217. doi: 10.1167/iovs.18-25788.

PMID:
30641549
3.

Current therapies and novel approaches for biliary diseases.

Rajapaksha IG, Angus PW, Herath CB.

World J Gastrointest Pathophysiol. 2019 Jan 5;10(1):1-10. doi: 10.4291/wjgp.v10.i1.1. Review.

4.

Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation.

Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW.

JGH Open. 2018 Sep 19;2(6):288-294. doi: 10.1002/jgh3.12086. eCollection 2018 Dec.

5.

Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand.

Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughan G, Crawford M, Angus P, Jones R, Gane E, Munn S, Macdonald G, Fawcett J, Wigg A, Chen J, Fink M, Adams LA.

Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361.

PMID:
30609187
6.

Reproductive Endocrinology of Non-Alcoholic Fatty Liver Disease.

Grossmann M, Wierman ME, Angus P, Handelsman DJ.

Endocr Rev. 2018 Nov 30. doi: 10.1210/er.2018-00158. [Epub ahead of print]

PMID:
30500887
7.

Outcome of Acetaminophen-Induced Acute Liver Failure Managed Without Intracranial Pressure Monitoring or Transplantation.

Porteous J, Cioccari L, Ancona P, Osawa E, Jones K, Gow P, Angus P, Warrillow S, Bellomo R.

Liver Transpl. 2019 Jan;25(1):35-44. doi: 10.1002/lt.25377.

PMID:
30379388
8.

Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients.

Asgari S, Chaturvedi N, Scepanovic P, Hammer C, Semmo N, Giostra E, Müllhaupt B, Angus P, Thompson AJ, Moradpour D, Fellay J.

J Viral Hepat. 2019 Feb;26(2):271-277. doi: 10.1111/jvh.13019. Epub 2018 Nov 6.

PMID:
30315682
9.

Effects of angiotensin-(1-7) and angiotensin II on vascular tone in human cirrhotic splanchnic vessels.

Casey S, Herath C, Rajapaksha I, Jones R, Angus P.

Peptides. 2018 Oct;108:25-33. doi: 10.1016/j.peptides.2018.08.008. Epub 2018 Sep 1.

PMID:
30179652
10.

The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice.

Rajapaksha IG, Mak KY, Huang P, Burrell LM, Angus PW, Herath CB.

Sci Rep. 2018 Jul 5;8(1):10175. doi: 10.1038/s41598-018-28490-y.

11.

Exploring the feasibility of targeted chronic hepatitis B screening in the emergency department: A pilot study.

Brock C, Yi Y, Papaluca T, Lucas B, Angus PW, Taylor D, Leung C.

Emerg Med Australas. 2018 Dec;30(6):864-866. doi: 10.1111/1742-6723.13118. Epub 2018 Jun 9.

PMID:
29885209
12.

Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation.

Sood S, Haifer C, Yu L, Pavlovic J, Gow PJ, Jones RM, Visvanathan K, Angus PW, Testro AG.

Transpl Infect Dis. 2018 Oct;20(5):e12934. doi: 10.1111/tid.12934. Epub 2018 Jun 19.

PMID:
29809312
13.

Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.

Bruinstroop E, Dalan R, Cao Y, Bee YM, Chandran K, Cho LW, Soh SB, Teo EK, Toh SA, Leow MKS, Sinha RA, Sadananthan SA, Michael N, Stapleton HM, Leung C, Angus PW, Patel SK, Burrell LM, Lim SC, Sum CF, Velan SS, Yen PM.

J Clin Endocrinol Metab. 2018 Jul 1;103(7):2698-2706. doi: 10.1210/jc.2018-00475.

PMID:
29718334
14.

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X.

Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25.

15.

Safety and effectiveness of umbilical hernia repair in patients with cirrhosis.

Hew S, Yu W, Robson S, Starkey G, Testro A, Fink M, Angus P, Gow P.

Hernia. 2018 Oct;22(5):759-765. doi: 10.1007/s10029-018-1761-9. Epub 2018 Mar 27.

PMID:
29589135
16.

Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).

McCaughan GW, Thwaites PA, Roberts SK, Strasser SI, Mitchell J, Morales B, Mason S, Gow P, Wigg A, Tallis C, Jeffrey G, George J, Thompson AJ, Parker FC, Angus PW; Australian Liver Association Clinical Research Network.

Aliment Pharmacol Ther. 2018 Feb;47(3):401-411. doi: 10.1111/apt.14404. Epub 2017 Dec 5.

PMID:
29205432
17.

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM.

Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4.

18.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.

Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.

19.

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome.

Mo A, Testro A, French J, Robertson M, Angus P, Grigg A.

Intern Med J. 2017 Dec;47(12):1361-1367. doi: 10.1111/imj.13544.

PMID:
28675622
20.

Acute oesophageal necrosis.

Khan SA, Thwaites PA, Braude M, Lontos S, Angus PW.

Lancet Gastroenterol Hepatol. 2016 Sep;1(1):84. doi: 10.1016/S2468-1253(16)30025-5. Epub 2016 Aug 10. No abstract available.

PMID:
28404118
21.

Elastosis perforans serpiginosa in a patient with Wilson's disease.

Thwaites PA, Khan SA, Asadi K, Angus PW.

Lancet Gastroenterol Hepatol. 2017 Feb;2(2):144. doi: 10.1016/S2468-1253(16)30212-6. Epub 2017 Jan 12. No abstract available.

PMID:
28403984
22.

Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy.

Sinclair M, Schelleman A, Sandhu D, Angus PW.

Hepatology. 2017 Sep;66(3):989-991. doi: 10.1002/hep.29151. Epub 2017 Jul 18.

PMID:
28295483
23.

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.

Mak KY, Rajapaksha IG, Angus PW, Herath CB.

Curr Gene Ther. 2017;17(1):4-16. doi: 10.2174/1566523217666170314141931.

PMID:
28292253
24.

Antibiotic Allergy Labels in a Liver Transplant Recipient Study.

Khumra S, Chan J, Urbancic K, Worland T, Angus P, Jones R, Grayson ML, Trubiano JA.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00078-17. doi: 10.1128/AAC.00078-17. Print 2017 May. No abstract available.

25.

A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation.

Sood S, Haifer C, Yu L, Pavlovic J, Churilov L, Gow PJ, Jones RM, Angus PW, Visvanathan K, Testro AG.

Liver Transpl. 2017 Apr;23(4):487-497. doi: 10.1002/lt.24730.

26.

Immune function biomarker QuantiFERON-monitor is associated with infection risk in cirrhotic patients.

Sood S, Yu L, Visvanathan K, Angus PW, Gow PJ, Testro AG.

World J Hepatol. 2016 Dec 18;8(35):1569-1575. doi: 10.4254/wjh.v8.i35.1569.

27.

Coagulation in acutely ill patients with severe chronic liver disease: Insights from thromboelastography.

Lloyd-Donald P, Vasudevan A, Angus P, Gow P, Mårtensson J, Glassford N, Eastwood GM, Hart GK, Bellomo R.

J Crit Care. 2017 Apr;38:215-224. doi: 10.1016/j.jcrc.2016.10.030. Epub 2016 Nov 4.

PMID:
27978499
28.

Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.

Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P.

Liver Int. 2017 Jun;37(6):827-835. doi: 10.1111/liv.13331. Epub 2016 Dec 22.

PMID:
27896895
29.

Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score.

Sinclair M, Gow PJ, Grossmann M, Shannon A, Hoermann R, Angus PW.

Liver Transpl. 2016 Nov;22(11):1482-1490. doi: 10.1002/lt.24607.

30.

Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.

Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ.

J Hepatol. 2016 Nov;65(5):906-913. doi: 10.1016/j.jhep.2016.06.007. Epub 2016 Jun 14.

PMID:
27312945
31.

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.

Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, Rivera LR, Furness JB, Forbes JM, Angus PW.

World J Gastroenterol. 2016 Sep 21;22(35):8026-40. doi: 10.3748/wjg.v22.i35.8026.

32.

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.

McElroy HJ, Roberts SK, Thompson AJ, Angus PW, McKenna SJ, Warren E, Musgrave S.

J Med Econ. 2017 Jan;20(1):72-81. Epub 2016 Sep 8.

PMID:
27552282
33.

Outpatient Terlipressin Infusion for the Treatment of Refractory Ascites.

Gow PJ, Ardalan ZS, Vasudevan A, Testro AG, Ye B, Angus PW.

Am J Gastroenterol. 2016 Jul;111(7):1041-2. doi: 10.1038/ajg.2016.168. No abstract available.

PMID:
27356836
34.

The role of the gut microbiota in NAFLD.

Leung C, Rivera L, Furness JB, Angus PW.

Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. doi: 10.1038/nrgastro.2016.85. Epub 2016 Jun 8. Review.

PMID:
27273168
35.

Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation.

Betz-Stablein BD, Töpfer A, Littlejohn M, Yuen L, Colledge D, Sozzi V, Angus P, Thompson A, Revill P, Beerenwinkel N, Warner N, Luciani F.

J Virol. 2016 Jul 27;90(16):7171-7183. doi: 10.1128/JVI.00243-16. Print 2016 Aug 15.

36.

Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.

Lim EJ, Chin R, Nachbur U, Silke J, Jia Z, Angus PW, Torresi J.

J Viral Hepat. 2016 Sep;23(9):730-43. doi: 10.1111/jvh.12541. Epub 2016 May 11.

PMID:
27167351
37.

Liver Failure Complicating a Febrile Illness in a Middle-Aged Man.

Vasudevan A, Ardalan Z, Angus P.

Gastroenterology. 2016 Jun;150(7):1542-1544. doi: 10.1053/j.gastro.2016.01.044. Epub 2016 May 3. No abstract available.

PMID:
27151259
38.

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.

Zeuzem S, Mantry P, Soriano V, Buynak RJ, Dufour JF, Pockros PJ, Wright D, Angus P, Buti M, Stern JO, Kadus W, Vinisko R, Böcher W, Mensa FJ.

Eur J Gastroenterol Hepatol. 2016 Aug;28(8):923-6. doi: 10.1097/MEG.0000000000000649.

PMID:
27140229
39.

High circulating oestrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease.

Sinclair M, Gow PJ, Angus PW, Hoermann R, Handelsman DJ, Wittert G, Martin S, Grossmann M.

Liver Int. 2016 Nov;36(11):1619-1627. doi: 10.1111/liv.13122. Epub 2016 Apr 6.

PMID:
26998685
40.

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X; SOLAR-2 investigators.

Lancet Infect Dis. 2016 Jun;16(6):685-697. doi: 10.1016/S1473-3099(16)00052-9. Epub 2016 Feb 18. Erratum in: Lancet Infect Dis. 2016 Jun;16(6):636.

PMID:
26907736
41.

Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions.

Sinclair M, Gow PJ, Grossmann M, Angus PW.

Aliment Pharmacol Ther. 2016 Apr;43(7):765-77. doi: 10.1111/apt.13549. Epub 2016 Feb 5. Review.

42.

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ.

Hepatology. 2016 May;63(5):1430-41. doi: 10.1002/hep.28473. Epub 2016 Mar 4.

43.

Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?

Elliott TR, Symes T, Kannourakis G, Angus P.

BMJ Case Rep. 2016 Jan 6;2016. pii: bcr2015213189. doi: 10.1136/bcr-2015-213189.

44.

Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant.

Adams LA, Arauz O, Angus PW, Sinclair M, MacDonald GA, Chelvaratnam U, Wigg AJ, Yeap S, Shackel N, Lin L, Raftopoulos S, McCaughan GW, Jeffrey GP; Australian New Zealand Liver Transplant Study Group.

J Gastroenterol Hepatol. 2016 May;31(5):1016-24. doi: 10.1111/jgh.13240.

PMID:
26589875
45.

Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.

Kazankov K, Rode A, Simonsen K, Villadsen GE, Nicoll A, Møller HJ, Lim L, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Vilstrup H, Frystyk J, Grønbæk H.

Scand J Clin Lab Invest. 2016;76(1):64-73. doi: 10.3109/00365513.2015.1099722. Epub 2015 Nov 7.

PMID:
26549495
46.

Medical Resource Utilisation of Australian Patients With Genotype 1 Chronic Hepatitis C: A Retrospective Observational Study.

McElroy H, Roberts S, Thompson A, Angus P, McKenna SJ, Warren E, Musgrave S.

Value Health. 2015 Nov;18(7):A632. doi: 10.1016/j.jval.2015.09.2238. Epub 2015 Oct 20. No abstract available.

47.

Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome.

Vasudevan A, Ardalan Z, Gow P, Angus P, Testro A.

Hepatology. 2016 Jul;64(1):316-8. doi: 10.1002/hep.28325. Epub 2015 Dec 22. No abstract available.

PMID:
26524479
48.

Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems.

Robertson M, Majumdar A, Boyapati R, Chung W, Worland T, Terbah R, Wei J, Lontos S, Angus P, Vaughan R.

Gastrointest Endosc. 2016 Jun;83(6):1151-60. doi: 10.1016/j.gie.2015.10.021. Epub 2015 Oct 26.

PMID:
26515955
49.

Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease.

Sinclair M, Grossmann M, Angus PW, Hoermann R, Hey P, Scodellaro T, Gow PJ.

J Gastroenterol Hepatol. 2016 Mar;31(3):661-7. doi: 10.1111/jgh.13182.

PMID:
26414812
50.

Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis.

Klein S, Herath CB, Schierwagen R, Grace J, Haltenhof T, Uschner FE, Strassburg CP, Sauerbruch T, Walther T, Angus PW, Trebicka J.

PLoS One. 2015 Sep 25;10(9):e0138732. doi: 10.1371/journal.pone.0138732. eCollection 2015.

Supplemental Content

Support Center